Farxiga Cost vs. Alternatives: Comparing SGLT2 Inhibitor Prices, Efficacy, and Value

How SGLT2 Inhibitors Work: The Shared Mechanism Behind Farxiga and Its Competitors

Every SGLT2 inhibitor on the market targets the same transporter protein in the kidney's proximal convoluted tubule. The sodium-glucose cotransporter 2 normally reabsorbs roughly 90% of filtered glucose back into the bloodstream. When dapagliflozin, empagliflozin, canagliflozin, or ertugliflozin blocks this protein, approximately 60 to 80 grams of glucose per day are excreted in the urine, lowering plasma glucose independent of insulin secretion.

This glucosuric effect produces a caloric deficit of roughly 240 to 320 calories daily. Blood pressure drops by 3 to 5 mmHg systolic on average due to mild osmotic diuresis and natriuresis. Body weight typically decreases by 2 to 3 kg over the first 12 to 24 weeks. These hemodynamic and metabolic effects appear to drive the cardiovascular and renal benefits seen across the class, though the exact cardioprotective mechanism remains under active investigation.

The selectivity profiles differ slightly between agents. Canagliflozin has measurable SGLT1 inhibitory activity at therapeutic doses, which may explain its higher rate of gastrointestinal side effects compared to dapagliflozin and empagliflozin. Ertugliflozin is the most SGLT2-selective agent in the class. These pharmacologic distinctions, however, have not translated into clear clinical superiority for any single drug in head-to-head trials.

Farxiga Pricing: What You Actually Pay in 2026

The list price tells only part of the story. AstraZeneca's wholesale acquisition cost (WAC) for Farxiga 10 mg sits near $580 for a 30-day supply, but actual out-of-pocket cost depends on insurance design, formulary placement, and manufacturer assistance programs.

For commercially insured patients, most large pharmacy benefit managers place Farxiga on Tier 3 (preferred brand). Typical copays range from $35 to $75 per month when dapagliflozin is the preferred SGLT2 inhibitor on a given plan. Some insurers prefer empagliflozin or canagliflozin instead, which can push Farxiga to non-preferred Tier 4 status with copays of $100 to $150 or higher. AstraZeneca offers a savings card program that may reduce copays to $0 for eligible commercially insured patients, with a maximum annual benefit.

Medicare Part D enrollees face different economics. SGLT2 inhibitors fall under the standard Part D benefit structure. Under the Inflation Reduction Act provisions that took effect in 2025, annual out-of-pocket prescription costs are capped at $2,000, which benefits patients taking multiple branded medications. Farxiga is included in most Medicare formularies, though step therapy requirements (trying metformin first) are common.

Uninsured patients face the full WAC. Cash-pay pricing through discount platforms like GoodRx or RxSaver can bring the monthly cost down to $480 to $530, still a substantial expense. This is where the upcoming generic entry could be transformational for access.

Head-to-Head Cost Comparison: Farxiga vs. Every SGLT2 Inhibitor

The four FDA-approved single-entity SGLT2 inhibitors in the U.S. market carry similar list prices, but their approved indication profiles differ considerably, which affects insurance coverage and real-world value.

Farxiga (dapagliflozin) 5 mg and 10 mg. WAC approximately $580 per month. FDA-approved for type 2 diabetes, heart failure (with reduced and preserved ejection fraction), and chronic kidney disease. The breadth of approved indications is the widest in the class, which can improve formulary access for patients with multiple qualifying conditions.

Jardiance (empagliflozin) 10 mg and 25 mg. WAC approximately $590 per month. FDA-approved for type 2 diabetes, heart failure (HFrEF and HFpEF), and cardiovascular risk reduction in adults with type 2 diabetes. Jardiance does not carry an independent CKD indication, though the EMPA-KIDNEY trial demonstrated renal benefits.

Invokana (canagliflozin) 100 mg and 300 mg. WAC approximately $570 per month. FDA-approved for type 2 diabetes and diabetic nephropathy risk reduction. Carries a boxed warning history related to lower-limb amputation risk identified in the CANVAS trial, though subsequent analyses have questioned whether this risk is truly drug-specific or a class concern.

Steglatro (ertugliflozin) 5 mg and 15 mg. WAC approximately $340 per month, making it the lowest-cost branded SGLT2 inhibitor. However, the VERTIS-CV trial showed non-inferiority for major adverse cardiovascular events but did not demonstrate superiority for cardiovascular or renal outcomes. This limits its appeal for patients prescribed an SGLT2 inhibitor specifically for heart failure or kidney protection.

The price difference between agents is modest at list price. The real cost gap emerges at the formulary level, where preferred status can mean the difference between a $35 copay and a $150 copay.

Clinical Value: What the Landmark Trials Actually Showed

Cost cannot be evaluated without efficacy data. The SGLT2 inhibitor class has generated an unusually strong evidence base across cardiovascular, renal, and metabolic endpoints.

The DAPA-HF trial (N=4,744) randomized patients with heart failure and reduced ejection fraction (LVEF ≤40%) to dapagliflozin 10 mg or placebo on top of standard therapy. The primary composite endpoint of worsening heart failure or cardiovascular death was reduced by 26% (HR 0.74, 95% CI 0.65 to 0.85, P<0.001). This benefit was consistent regardless of diabetes status. The number needed to treat (NNT) was 21 over a median follow-up of 18.2 months.

The DAPA-CKD trial (N=4,304) showed dapagliflozin reduced the composite of sustained eGFR decline ≥50%, end-stage kidney disease, or renal/cardiovascular death by 39% versus placebo (HR 0.61, 95% CI 0.51 to 0.72, P<0.001). The trial was stopped early for efficacy. Benefits were observed across patients with and without type 2 diabetes, and across IgA nephropathy, focal segmental glomerulosclerosis, and diabetic kidney disease subtypes.

For empagliflozin, the EMPA-REG OUTCOME trial (N=7,020) demonstrated a 14% reduction in the primary composite of cardiovascular death, nonfatal MI, or nonfatal stroke in patients with type 2 diabetes and established cardiovascular disease. Cardiovascular death alone was reduced by 38%. The EMPEROR-Reduced and EMPEROR-Preserved trials subsequently confirmed heart failure benefits across ejection fraction ranges.

Dr. John McMurray, lead investigator of DAPA-HF, stated: "The magnitude and consistency of benefit with dapagliflozin in heart failure were remarkable, and the findings applied equally to patients with and without diabetes."

The 2022 AHA/ACC/HFSA heart failure guidelines give SGLT2 inhibitors a Class I recommendation (Level of Evidence A) for patients with heart failure regardless of ejection fraction. Dr. Paul Heidenreich, chair of the writing committee, noted: "SGLT2 inhibitors represent one of the most significant advances in heart failure treatment in the past decade."

Generic Dapagliflozin: When Will It Arrive and What Will It Cost?

AstraZeneca's core composition-of-matter patent for dapagliflozin has an expected expiration in 2026. Several generic manufacturers have filed Abbreviated New Drug Applications (ANDAs) with the FDA. Generic entry could reduce costs by 70% to 90% based on historical patterns with other branded oral medications.

The generic pricing trajectory of other cardiovascular drugs provides a useful benchmark. When atorvastatin (Lipitor) lost patent exclusivity, generic pricing dropped from roughly $170 per month to under $15 within two years. Losartan generics fell from approximately $90 to $4 per month over a similar period. If dapagliflozin follows this pattern, monthly costs could eventually fall to $50 to $100 in the first year of generic availability and potentially below $30 within three years.

This timeline matters for cost-conscious prescribing decisions right now. A patient stable on Farxiga may benefit from continuing current therapy and waiting for generic entry rather than switching to a different branded SGLT2 inhibitor. Switching agents solely for minor cost differences of $10 to $20 per month exposes the patient to a new adverse-effect profile without meaningful savings.

No generic empagliflozin is expected before 2028. Canagliflozin generic entry timelines remain uncertain due to ongoing patent litigation. Ertugliflozin's relatively weak cardiovascular outcome data make it a less attractive option even at its lower list price.

Insurance and Formulary Strategies: Getting the Lowest Possible Cost

Formulary placement is the single largest determinant of out-of-pocket cost for SGLT2 inhibitors. A few practical strategies can reduce what patients actually pay.

Check preferred status first. Before prescribing any SGLT2 inhibitor, verify which agent is preferred on the patient's specific formulary. The three major PBMs (CVS Caremark, Express Scripts, OptumRx) each maintain different preferred agent designations, and these change annually. Prescribing the preferred agent can reduce copays by $50 to $100 per month compared to a non-preferred alternative with identical clinical efficacy.

Use prior authorization proactively. When Farxiga is clinically indicated but non-preferred, a prior authorization citing the specific approved indication (heart failure, CKD) and relevant trial data (DAPA-HF, DAPA-CKD) improves approval rates substantially. Documenting that the patient meets trial inclusion criteria strengthens the case.

Stack manufacturer and plan benefits. AstraZeneca's copay card can be used in conjunction with commercial insurance. Patients with commercial coverage and a $75 copay may reduce this to $0 with the manufacturer card, though Medicare and Medicaid beneficiaries are ineligible for manufacturer copay assistance by federal law.

Consider combination products. Qtern (dapagliflozin plus saxagliptin) and Xigduo XR (dapagliflozin plus metformin XR) may be preferred on some formularies. If a patient is already taking both components, a combination tablet might carry a lower copay than two separate prescriptions.

Patient assistance programs. AstraZeneca's AZ&Me prescription savings program provides free medication to qualifying uninsured patients with household incomes below 400% of the federal poverty level.

Safety Profile Comparison: Cost of Complications Matters Too

The total cost of an SGLT2 inhibitor includes managing its adverse effects. Across the class, the most common side effects are genital mycotic infections (occurring in 5% to 10% of women and 3% to 5% of men), urinary tract infections, volume depletion, and, rarely, diabetic ketoacidosis (DKA).

Canagliflozin carries unique safety signals. The CANVAS program identified a roughly twofold increase in lower-limb amputation risk (6.3 vs. 3.4 per 1,000 patient-years). While the FDA subsequently removed the boxed warning in 2020 after broader data review, many clinicians remain cautious prescribing canagliflozin to patients with peripheral vascular disease.

Dapagliflozin and empagliflozin have not shown a statistically significant amputation signal in their respective outcome trials. The DKA risk is comparable across agents, estimated at 0.1% to 0.3% per year, and occurs predominantly in patients with type 1 diabetes (off-label use) or during acute illness with insulin dose reduction.

One hidden cost factor: genital mycotic infections. While generally mild and treatable with a single dose of oral fluconazole ($4 to $10 generic), recurrent episodes affect approximately 2% to 3% of patients and may lead to drug discontinuation. Counseling on perineal hygiene at the time of prescribing reduces this risk. Treatment for a single episode costs less than $15, but the clinical time and patient frustration of recurrent infections should factor into the value equation.

Which SGLT2 Inhibitor Offers the Best Value by Indication?

The answer depends on why the drug is being prescribed.

For type 2 diabetes alone. All four agents produce comparable A1C reductions of 0.5% to 0.8% from baseline. Steglatro at $340 per month offers the lowest list price, but its weaker cardiovascular outcome data (VERTIS-CV showed non-inferiority only) make it a less complete long-term investment. The preferred agent on the patient's formulary is the best choice, since clinical differences for glycemic control alone are negligible.

For heart failure. Dapagliflozin (DAPA-HF) and empagliflozin (EMPEROR-Reduced, EMPEROR-Preserved) both carry FDA approval and strong outcome data. Choose the one preferred on formulary. If both are equally accessible, dapagliflozin's earlier expected generic entry gives it a slight edge for long-term cost planning.

For chronic kidney disease. Dapagliflozin is the only SGLT2 inhibitor with a standalone FDA approval for CKD across both diabetic and non-diabetic etiologies, based on DAPA-CKD. This can simplify prior authorization for CKD patients without diabetes. Canagliflozin carries a narrower renal indication limited to diabetic nephropathy, based on CREDENCE.

For patients with peripheral vascular disease. Avoid canagliflozin given the amputation signal from CANVAS. Dapagliflozin or empagliflozin are preferred. Cost difference between these two is minimal.

The 2026 Cost Outlook: Generic Entry Changes Everything

The SGLT2 inhibitor market is approaching a major inflection point. When generic dapagliflozin enters the market, it will likely become the default first-line SGLT2 inhibitor for cost reasons alone. A $30 to $50 generic dapagliflozin with DAPA-HF and DAPA-CKD level evidence would shift prescribing patterns the way generic atorvastatin displaced branded statins after 2011.

Prescribers writing new SGLT2 inhibitor prescriptions in 2026 should consider this timeline. Starting a patient on Farxiga now positions them for a smooth transition to generic dapagliflozin when available. Starting on Jardiance locks the patient into a branded product with a later patent expiration and a potential future switch that carries its own adherence risks.

For patients currently stable on any SGLT2 inhibitor, switching solely based on current cost differences of $10 to $30 per month is generally not justified. The ADA Standards of Care recommend against switching medications that are working well unless there is a clear clinical or safety rationale.

The most cost-effective SGLT2 inhibitor prescription in mid-2026 is whichever agent is preferred on the patient's formulary today, with a plan to transition to generic dapagliflozin when FDA-approved generic versions reach pharmacy shelves. Verify formulary status before each renewal, apply manufacturer copay assistance where eligible, and document the specific indication (diabetes, HF, or CKD) to maximize prior authorization approval rates.